Coinbase 在加密货币交易所的上市路线图中加入两个项目后，激发了山寨币的上涨行情
Coinbase has added two altcoins, Bio Protocol (BIO) and Euler (EUL), to its listing roadmap, leading to price rallies for both projects. BIO is currently trading at $0.06963, up 9.1%, while EUL rose from $12.63 to $14.12 following the announcement. The listing roadmap aims to enhance transparency and prevent frontrunning of trading support announcements. BIO focuses on biotechnology funding, while EUL is a governance token for a DeFi lending platform.
Coinbase has added two altcoins to its listing roadmap, sparking rallies for the projects’ digital assets.
The exchange announced Bio Protocol (BIO), a biotechnology-related project, and the decentralized finance (DeFi) lending platform Euler (EUL) may soon be available to trade by its customers.
Being added to Coinbase’s listing roadmap means that the top US crypto exchange is considering rolling out trading support for the asset in the near future. The roadmap was established in 2022 to increase transparency and reduce the possibility of investors frontrunning new trading support announcements.
Amid the news, BIO is trading for $0.06963 at time of writing, up 9.1% in the last 24 hours. BIO is down from its day’s high of $0.07799.
Meanwhile, EUL was trading for a recent low of $12.63 before soaring to $14.12 after Coinbase’s announcement. At time of writing, EUL has since returned to the $13 range.
BIO is the native token of the Bio Protocol platform that aims to “accelerate biotechnology by giving global communities of patients, scientists and biotech professionals the ability to collectively fund, build and own tokenized biotech projects and intellectual property,” according to the project’s website.
EUL is the native governance token of the Euler protocol, which aims to make “lending and borrowing simpler, more efficient, and more versatile, while giving users the freedom to explore new opportunities in DeFi,” according to its website.
